Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top

International Journal of Clinical Oncology

Issue 6/2025 Including Invited Reviews on Paradigm shift in therapy for biliary tract cancer

Content (23 Articles)

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of amivantamab plus lazertinib for non-small cell lung cancer, durvalumab for small cell lung cancer, tislelizumab for esophageal cancer, tisotumab vedotin for cervical cancer, ivosidenib for leukemia, and venetoclax for lymphoma in Japan

  • NSCLC
  • PMDA Regulatory Update

Noriomi Matsumura, Masaki Mandai

Safety of laparoscopic surgery for ovarian tissue cryopreservation in pediatric patients

Haruhiro Kondo, Seido Takae, Shigeyuki Furuta, Miki Sakamoto, Juma Obayashi, Dai Keino, Kentaro Nakamura, Kunihide Tanaka, Takuya Kawaguchi, Mika Mori, Natsumi Furuya, Mikiko Nishioka, Yuki Suzuki-Takahashi, Chiai Nagae, Yodo Sugishita, Yuki Horage-Okutsu, Tetsuya Mori, Naoki Shimizu, Hiroaki Kitagawa, Nao Suzuki

Revisiting resectability of biliary tract cancers, in the triplet drug therapy era with immune checkpoint inhibitors

Shogo Kobayashi, Daisaku Yamada, Yuichiro Doki, Hidetoshi Eguchi

Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies

Daisaku Yamada, Shogo Kobayashi, Yuichiro Doki, Hidetoshi Eguchi

Efficacy and safety of cancer vaccine therapy in malignant melanoma: a systematic review

Takeshi Seta, Shohei Nakamura, Mitsuaki Oura, Kazuki Yokoyama, Yoshitaka Nishikawa, Nobuaki Hoshino, Kiichiro Ninomiya, Tatsunori Shimoi, Katsuyuki Hotta, Takeo Nakayama

Serum amylase level as a predictive biomarker for persistent grade 1 chemotherapy-associated oral mucositis: a retrospective cross-sectional study

Nursema Ozdemir, Ali Alkan, Ozgur Tanriverdi

Evaluation of drug lag and drug loss in Japan: participation in global phase III oncology trials

Kaname Shiga, Taro Shibata, Toshio Miyata

Prognostic prediction using recursive partitioning analysis of patients undergoing salvage surgery for locally recurrent oral squamous cell carcinoma

Toshihiko Sakai, Go Omura, Kohtaro Eguchi, Azusa Sakai, Yoshifumi Matsumoto, Chihiro Fushimi, Seiichi Yoshimoto

Improved local control and survival outcomes with RADPLAT in T4 oropharyngeal cancer: a retrospective study

Satoshi Kano, Takayoshi Suzuki, Daisuke Yoshida, Nayuta Tsushima, Hiroshi Idogawa, Ryohei Katsumata, Koichi Yasuda, Naoya Kinota, Koji Yamasaki, Yasushi Shimizu, Jun Taguchi, Hidefumi Aoyama, Akihiro Homma

Concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with head and neck squamous cell carcinoma: survival analysis based on 2-year follow-up data

  • Original Article

Yushi Ueki, Yuki Ohno, Shusuke Ohshima, Yusuke Yokoyama, Jo Omata, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Kohei Ohtaki, Kohei Saijo, Ryoko Tanaka, Nao Takahashi, Ryuichi Okabe, Arata Horii

Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancer

Ryutaro Onaga, Tomohiro Enokida, Shingo Sakashita, Nobukazu Tanaka, Yuta Hoshi, Takuma Kishida, Ryo Kuboki, Takao Fujisawa, Susumu Okano, Hiroshi Nishino, Makoto Ito, Genichiro Ishii, Shumpei Ishikawa, Makoto Tahara

Comparison of the prognostic effect of taxane regimens combined with ramucirumab before nivolumab for advanced gastric cancer

Yoshinori Kikuchi, Yoko Oshima, Muneharu Fujisaki, Mao Tsuru, Hidejiro Urakami, Sakae Nagaoka, Nobue Futawatari, Satoshi Yajima, Hideaki Shimada

A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study

Toru Aoyama, Akira Ooki, Koji Oba, Kazuhiro Nishikawa, Ryohei Kawabata, Michitaka Honda, Hiromichi Maeda, Mitsuro Kanda, Keiji Sugiyama, Akitaka Makiyama, Kenki Segami, Masazumi Takahashi, Yoshiaki Shindo, Tsutomu Namikawa, Takashi Oshima, Aya Katayama, Kazuhito Shiosakai, Junichi Sakamoto

Efficacy and safety of postoperative adjuvant chemotherapy with oxaliplatin for elderly patients: results from the CCOG-1302 study

Shinichi Umeda, Goro Nakayama, Takayoshi Kishida, Norifumi Hattori, Koki Nakanishi, Haruyoshi Tanaka, Dai Shimizu, Hideki Takami, Masamichi Hayashi, Mitsuro Kanda, Chie Tanaka, Yasuhiro Kodera

Survival paradox and effect of adjuvant chemotherapy for high-risk Stage II and low-risk Stage III colorectal cancer

Keisuke Noda, Tetsuro Tominaga, Takashi Nonaka, Rika Ono, Kaido Oishi, Yuma Takamura, Toshio Shiraishi, Shintaro Hashimoto, Makoto Hisanaga, Hiroaki Takeshita, Mitsutoshi Ishii, Shosaburo Oyama, Kazuhide Ishimaru, Terumitsu Sawai, Keitaro Matsumoto

Simple definition of biologically borderline resectable colorectal liver metastases based on early surgical failure

Kenei Furukawa, Masashi Tsunematsu, Koichiro Haruki, Shinji Onda, Kyohei Abe, Michinori Matsumoto, Tomohiko Taniai, Mitsuru Yanagaki, Yoichi Toyama, Toru Ikegami

Conditions for effective use of liposomal irinotecan with fluorouracil and leucovorin in unresectable pancreatic cancer after FOLFIRINOX treatment

  • Original Article

Yasuyuki Okada, Yasushi Sato, Ryo Shinomiya, Takanori Miyake, Taku Takahashi, Reiko Yokoyama, Yasuhiro Mitsui, Tetsu Tomonari, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Yutaka Kawano, Tetsuji Takayama

Long-term results of dynamic tumor-tracking stereotactic body radiotherapy with real-time monitoring using a gimbal-mounted linac for liver tumors: a multicenter observational study

Yusuke Iizuka, Minoru Inoue, Masaki Kokubo, Takashi Sakamoto, Keiko Nemoto Murofushi, Toshiyuki Imagumbai, Takuya Shimizuguchi, Masahiro Hiraoka, Takashi Mizowaki

Prognostic impact of dose reduced S-1 adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: a retrospective multicenter study

Kazuki Kobayashi, Takahiro Einama, Yoichi Miyata, Asuma Ide, Naoto Yonamine, Takazumi Tsunenari, Mikiya Takao, Masato Yamadera, Makoto Nishikawa, Akifumi Kimura, Eiji Shinto, Hideki Ueno, Yoshifumi Beck, Yoji Kishi

Adverse events of hepatic function disorder in Japanese patients with radically unresectable or metastatic renal cell carcinoma treated with pembrolizumab plus axitinib: a post-marketing surveillance study

Mototsugu Oya, Shotaro Yasuoka, Takuto Tokudome, Toshihiko Minegishi, Masahiro Hamada, Masahiko Ozaki, Shinichiroh Maekawa, Yuichiro Ito

Prognostic factors and effect of existing predictive models in oligo-metastatic urothelial carcinoma (YUSHIMA study)

Kenji Tanabe, Soichiro Yoshida, Tomoki Kimura, Yuya Maezawa, Kensaku Ishihara, Naoki Inoue, Keita Izumi, Motohiro Fujiwara, Masahiro Toide, Takanobu Yamamoto, Sho Uehara, Saori Araki, Masaharu Inoue, Ryoji Takazawa, Noboru Numao, Yukihiro Ohtsuka, Hajime Tanaka, Yasuhisa Fujii

Utility of circulating human papillomavirus DNA as a biomarker for detection and prognosis of cervical cancer in Japanese patients

Tomoko Taguchi, Minako Yokoyama, Toshitsugu Fujita, Satoka Tanba, Hiroe Oikiri, Yuki Osawa, Yukiko Matsumura, Tatsuhiko Shigeto, Yoshihito Yokoyama, Hodaka Fujii

Correction: The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis

Ke Xu, Tao Liu, Jie Zhang, Yangang Zhou, Fang Yang, Tao Ren

May 25
Issue: 5/2025
Jul 25
Issue: 7/2025

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Case simulations: Biomarker-driven management of NSCLC (Link opens in a new window)

Do you want to assess your biomarker testing skills and management decisions? Use these simulation-based case studies based on realistic NSCLC scenarios to do so in a practical and secure environment.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
COMMISSIONED

How-to guide for healthcare professionals: understanding genomic reports

This educational activity was initiated, funded and co-developed by Boehringer Ingelheim and is intended for healthcare professionals in the UK and Ireland only. 

Genomic testing helps inform cancer diagnosis, prognosis, and treatment. A genomic report is generated by the laboratory carrying out next-generation sequencing to analyze biopsy samples. Access this educational microsite to learn more about typical genomic report content and how to interpret test results for patients with cancer.

NP-GB-106631 | Jan 2026

Commissioned by:
  • Boehringer Ingelheim
Learn more
Image Credits
Biomarker-driven management of NSCLC logo/© Springer Health+ IME, DNA double helix structure on a purple background/© 2025 Adobe